New and Emerging Practice Standards in ES-SCLC episode artwork

EPISODE · Dec 11, 2025 · 38 MIN

New and Emerging Practice Standards in ES-SCLC

from Conversations in Lung Cancer Research · host Dr. Rebecca Tay, A/Prof Surein Arulananda, Dr. Dasantha Jayamanne (DJ)

In this episode of 'Conversations in Lung Cancer Research,' host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment.They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape.This episode is sponsored by Roche.TOGA's SCLC Masterclass will take place 20 March 2026, at Novotel on Collins, MelbourneAn advanced workshop covering evolving standards of care and new therapies in SCLC.Early bird tickets available until 16 Feb 2026 > https://thoraciconcology.org.au/events/masterclass-small-cell-lung-cancer/RESOURCES AND LINKS:CREST trial https://pmc.ncbi.nlm.nih.gov/articles/PMC3058352/Caspian Study https://www.sciencedirect.com/science/article/pii/S1525730425001640CHEST RT https://trog.com.au/trials/trog-20-01-chest-rt/DeLLphi-303 https://www.annalsofoncology.org/article/S0923-7534(25)04288-7/fulltextIMforte https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006Japan study PCI vs MRIhttps://pubmed.ncbi.nlm.nih.gov/28343976/TIMESTAMPS:(00:00) Introduction and Acknowledgements(00:36) Overview of Small Cell Lung Cancer(02:03) Current First-Line Treatments(06:59) Radiotherapy in Small Cell Lung Cancer(11:36) New Developments in Maintenance and Second-Line Treatments(15:35) Exciting New Therapies and Future Directions(24:01) Radiotherapy and Immune Engaging Therapies(32:53) Conclusion and Future EventsKEYWORDS: SCLC, ES-SCLC, Small Cell Lung Cancer, Early Stage Small Cell Lung Cancer Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube:  https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Episode metadata supplied by the publisher feed · Published Dec 11, 2025

Embed this episode

In this episode of 'Conversations in Lung Cancer Research,' host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment. They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

New and Emerging Practice Standards in ES-SCLC

0:00 38:56

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Conversations in Lung Cancer Research?

This episode is 38 minutes long.

When was this Conversations in Lung Cancer Research episode published?

This episode was published on December 11, 2025.

Can I download this Conversations in Lung Cancer Research episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!